338 related articles for article (PubMed ID: 15279677)
1. Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors.
Douin V; Bornes S; Creancier L; Rochaix P; Favre G; Prats AC; Couderc B
BMC Biotechnol; 2004 Jul; 4():16. PubMed ID: 15279677
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout.
Harries M; Phillipps N; Anderson R; Prentice G; Collins M
J Gene Med; 2000; 2(4):243-9. PubMed ID: 10953915
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12.
Zitvogel L; Tahara H; Cai Q; Storkus WJ; Muller G; Wolf SF; Gately M; Robbins PD; Lotze MT
Hum Gene Ther; 1994 Dec; 5(12):1493-506. PubMed ID: 7711142
[TBL] [Abstract][Full Text] [Related]
4. Stable MLV-VL30 dicistronic retroviral vectors with a VL30 or MoMLV sequence promoting both packaging of genomic RNA and expression of the 3' cistron.
Torrent C; Berlioz C; Darlix JL
Hum Gene Ther; 1996 Mar; 7(5):603-12. PubMed ID: 8845385
[TBL] [Abstract][Full Text] [Related]
5. Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscle.
Allera-Moreau C; Delluc-Clavières A; Castano C; Van den Berghe L; Golzio M; Moreau M; Teissié J; Arnal JF; Prats AC
BMC Biotechnol; 2007 Oct; 7():74. PubMed ID: 17963525
[TBL] [Abstract][Full Text] [Related]
6. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK
Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456
[TBL] [Abstract][Full Text] [Related]
7. Tricistronic and tetracistronic retroviral vectors for gene transfer.
De Felipe P; Izquierdo M
Hum Gene Ther; 2000 Sep; 11(13):1921-31. PubMed ID: 10986564
[TBL] [Abstract][Full Text] [Related]
8. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy.
Morgan RA; Couture L; Elroy-Stein O; Ragheb J; Moss B; Anderson WF
Nucleic Acids Res; 1992 Mar; 20(6):1293-9. PubMed ID: 1313966
[TBL] [Abstract][Full Text] [Related]
9. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site.
Sugimoto Y; Aksentijevich I; Gottesman MM; Pastan I
Biotechnology (N Y); 1994 Jul; 12(7):694-8. PubMed ID: 7764914
[TBL] [Abstract][Full Text] [Related]
10. Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.
Delluc-Clavières A; Le Bec C; Van den Berghe L; Conte C; Allo V; Danos O; Prats AC
Gene Ther; 2008 Aug; 15(15):1090-8. PubMed ID: 18369321
[TBL] [Abstract][Full Text] [Related]
11. Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.
Cheng X; Gao XC; Wang JP; Yang XY; Wang Y; Li BS; Kang FB; Li HJ; Nan YM; Sun DX
World J Gastroenterol; 2014 Dec; 20(48):18284-95. PubMed ID: 25561795
[TBL] [Abstract][Full Text] [Related]
12. The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site.
Byun J; Kim JM; Robbins PD; Kim S
Gene Ther; 1998 Oct; 5(10):1441-4. PubMed ID: 9930351
[TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferase.
Fan L; Owen JS; Dickson G
Atherosclerosis; 1999 Nov; 147(1):139-45. PubMed ID: 10525135
[TBL] [Abstract][Full Text] [Related]
14. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
15. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of internal ribosomal entry sites as molecular tools for bicistronic expression.
Sadikoglou E; Daoutsali E; Petridou E; Grigoriou M; Skavdis G
J Biotechnol; 2014 Jul; 181():31-4. PubMed ID: 24709397
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo comparison of viral and cellular internal ribosome entry sites for bicistronic vector expression.
Licursi M; Christian SL; Pongnopparat T; Hirasawa K
Gene Ther; 2011 Jun; 18(6):631-6. PubMed ID: 21368899
[TBL] [Abstract][Full Text] [Related]
18. High-throughput gateway bicistronic retroviral vectors for stable expression in mammalian cells: exploring the biologic effects of STAT5 overexpression.
Royer Y; Menu C; Liu X; Constantinescu SN
DNA Cell Biol; 2004 Jun; 23(6):355-65. PubMed ID: 15231069
[TBL] [Abstract][Full Text] [Related]
19. Development of a new bicistronic retroviral vector with strong IRES activity.
Martin P; Albagli O; Poggi MC; Boulukos KE; Pognonec P
BMC Biotechnol; 2006 Jan; 6():4. PubMed ID: 16409632
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an internal ribosomal entry segment within the 5' leader of avian reticuloendotheliosis virus type A RNA and development of novel MLV-REV-based retroviral vectors.
López-Lastra M; Gabus C; Darlix JL
Hum Gene Ther; 1997 Nov; 8(16):1855-65. PubMed ID: 9382952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
